In an advance towards conquering covid-19, doctors in Michigan say an antibody drug may sharply cut the chance patients on a ventilator will die.
The problem: The pandemic viral disease is infecting millions and for those who end up on a ventilator in an ICU, the odds are grim. More than half are dying.
The drug: Doctors at the University of Michigan set out to control the haywire immune reaction that pushes some covid-19 patients into a death spiral. To do it, they gave 78 patients on ventilators the drug tocilizumab, which blocks IL-6, a molecule in the body that sets off a reacting to an infection. (The drug is sold by Roche under the tradename Acterma.)
The result: The doctors say in a preprint that patients who got the drug were 45% less likely to die than those who didn’t. But there’s a big caveat to the result, which is that the doctors knew which patients got the drug, and which didn’t. Their picks could have been biased— people more likely to improve anyway, for example—so further studies are needed.
Emerging cocktail: In late May, Roche said it would start a trial to combine its IL-6 blocker combined with remdesivir, an antiviral drug with modest benefits that got emergency approval in the US for treating covid-19. That drug is meant to block the virus from replicating.
By combining the two drugs, doctors may be closing in on a cocktail able to cut the death rate from the virus, a step that would help society return to normal.